Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Chronic Heart Failure

Free Subscription Articles published in Cardiovasc Res Retrieve available abstracts of 121 articles: HTML format

Single Articles

April 2024
1. KASS DA
   Benchmarking pre-clinical heart failure with preserved ejection fraction models: can we do better?
   Cardiovasc Res. 2024 Apr 4:cvae059. doi: 10.1093.
   PubMed    
   
   
   March 2024
2. RANGREZ AY, Frey N
   Reverse cardio-oncology: is heart failure-mediated gut dysbiosis the mechanistic driver of colorectal cancer progression?
   Cardiovasc Res. 2024 Mar 28:cvae051. doi: 10.1093.
   PubMed    
   
   
   
3. KESIDOU D, Beqqali A, Baker AH
   The dual effects of miR-222 in cardiac hypertrophy: bridging pathological and physiological paradigms.
   Cardiovasc Res. 2024;120:217-219.
   PubMed    
   
   
   February 2024
4. KIZER JR
   The elusive quest for causality in adiponectin's bimodal relationship with cardiovascular disease: Mendelian randomization meets Janus.
   Cardiovasc Res. 2024;120:3-5.
   PubMed    
   
   
   
5. ROLSKI F, Tkacz K, Weglarczyk K, Kwiatkowski G, et al
   TNF-alpha protects from exacerbated myocarditis and cardiac death by suppressing expansion of activated heart-reactive CD4+ T cells.
   Cardiovasc Res. 2024;120:82-94.
   PubMed     Abstract available
   
   
   
6. DE WIT S, Geerlings L, Shi C, Dronkers J, et al
   Heart failure-induced microbial dysbiosis contributes to colonic tumour formation in mice.
   Cardiovasc Res. 2024 Feb 24:cvae038. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. GOTTHARDT M, Lehnart SE
   SERCA2a microdomain cAMP changes in heart failure with preserved ejection fraction.
   Cardiovasc Res. 2024 Feb 9:cvae030. doi: 10.1093.
   PubMed    
   
   
   January 2024
8. SUN Q, Guven B, Wagg CS, de Oliveira AA, et al
   Mitochondrial fatty acid oxidation is the major source of cardiac ATP production in heart failure with preserved ejection fraction.
   Cardiovasc Res. 2024 Jan 9:cvae006. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. ABOULEISA RRE, Tang XL, Ou Q, Salama AM, et al
   Gene therapy encoding cell cycle factors to treat chronic ischemic heart failure in rats.
   Cardiovasc Res. 2024 Jan 4:cvae002. doi: 10.1093.
   PubMed     Abstract available
   
   
   December 2023
10. LAI P, Hille SS, Subramanian H, Weigman R, et al
    Remodelling of cAMP dynamics within the SERCA2a microdomain in heart failure with preserved ejection fraction caused by obesity and type 2 diabetes.
    Cardiovasc Res. 2023 Dec 14:cvad178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. LIU X, Li H, Hastings MH, Xiao C, et al
    miR-222 inhibits pathological cardiac hypertrophyand heart failure.
    Cardiovasc Res. 2023 Dec 12:cvad184. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
12. KATTIH B, Boeckling F, Shumliakivska M, Tombor L, et al
    Single-nuclear transcriptome profiling identifies persistent fibroblast activation in hypertrophic and failing human hearts of patients with longstanding disease.
    Cardiovasc Res. 2023;119:2550-2562.
    PubMed     Abstract available
    
    
    
13. CICCARELLI M, Pires IF, Bauersachs J, Bertrand L, et al
    Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial Function.
    Cardiovasc Res. 2023;119:2390-2404.
    PubMed     Abstract available
    
    
    
14. CORRADI F, Masini G, Bucciarelli T, De Caterina R, et al
    Iron deficiency in myocardial ischaemia: molecular mechanisms and therapeutic perspectives.
    Cardiovasc Res. 2023;119:2405-2420.
    PubMed     Abstract available
    
    
    
15. WU J, Subbaiah KCV, Hedaya O, Chen S, et al
    FAM210A regulates mitochondrial translation and maintains cardiac mitochondrial homeostasis.
    Cardiovasc Res. 2023;119:2441-2457.
    PubMed     Abstract available
    
    
    
16. BECHMANN LE, Emanuelsson F, Nordestgaard BG, Benn M, et al
    Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose.
    Cardiovasc Res. 2023;119:2482-2493.
    PubMed     Abstract available
    
    
    
17. ASHOUR D, Rebs S, Arampatzi P, Saliba AE, et al
    An interferon gamma response signature links myocardial aging and immunosenescence.
    Cardiovasc Res. 2023;119:2458-2468.
    PubMed     Abstract available
    
    
    October 2023
18. NIELSEN MB, Colak Y, Benn M, Mason A, et al
    Plasma adiponectin levels and risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction: large scale observational and Mendelian randomization evidence.
    Cardiovasc Res. 2023 Oct 28:cvad162. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. CUTHBERT JJ, Cleland JGF
    Should we resurrect acetazolamide as a diuretic for congestion due to heart failure?
    Cardiovasc Res. 2023 Oct 18:cvad148. doi: 10.1093.
    PubMed    
    
    
    September 2023
20. ZOCCALI C, Mallamaci F, Adamczak M, de Oliveira RB, et al
    Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association.
    Cardiovasc Res. 2023;119:2017-2032.
    PubMed     Abstract available
    
    
    August 2023
21. CHEN X, Li X, Wu X, Ding Y, et al
    Integrin beta-like 1 mediates fibroblast-cardiomyocyte crosstalk to promote cardiac fibrosis and hypertrophy.
    Cardiovasc Res. 2023;119:1928-1941.
    PubMed     Abstract available
    
    
    
22. VISTNES M, Erusappan PM, Sasi A, Norden ES, et al
    Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction.
    Cardiovasc Res. 2023;119:1915-1927.
    PubMed     Abstract available
    
    
    July 2023
23. MARTIN TP, MacDonald EA, Bradley A, Watson H, et al
    RNA interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction.
    Cardiovasc Res. 2023 Jul 11:cvad107. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. DA DALT L, Cabodevilla AG, Goldberg IJ, Norata GD, et al
    Cardiac lipid metabolism, mitochondrial function and heart failure.
    Cardiovasc Res. 2023 Jul 1:cvad100. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
25. DAMMAN K, Testani J
    Cardiorenal interactions in heart failure - insights from recent therapeutic advances.
    Cardiovasc Res. 2023 Jun 26:cvad096. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. SMART CD, Fehrenbach DJ, Wassenaar JW, Agrawal V, et al
    Immune profiling of murine cardiac leukocytes identifies Trem2 as a novel mediator of hypertensive heart failure.
    Cardiovasc Res. 2023 Jun 14:cvad093. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. CHUNG B, Wang Y, Thiel M, Rostami F, et al
    Preemptive iron supplementation prevents myocardial iron deficiency and attenuates adverse remodelling after myocardial infarction.
    Cardiovasc Res. 2023 Jun 14:cvad092. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. BASSUK SS, Manson JE
    Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence.
    Cardiovasc Res. 2023;119:1297-1309.
    PubMed     Abstract available
    
    
    
29. KANY S, Al-Taie C, Roselli C, Pirruccello JP, et al
    Association of genetic risk and outcomes in patients with atrial fibrillation: interactions with early rhythm control in the EAST-AFNET4 trial.
    Cardiovasc Res. 2023 Jun 2:cvad027. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2023
30. GROGAN A, Lucero EY, Jiang H, Rockman HA, et al
    Pathophysiology and pharmacology of G protein-coupled receptors in the heart.
    Cardiovasc Res. 2023;119:1117-1129.
    PubMed     Abstract available
    
    
    
31. 
    Corrigendum to: VEGF-B hypertrophy predisposes to transition from diastolic to systolic heart failure in hypertensive rats.
    Cardiovasc Res. 2023 May 15:cvad073. doi: 10.1093.
    PubMed    
    
    
    
32. DONG M, Chen D, Zhu Y, Yang S, et al
    Impaired regulation of MMP2/16-MLCK3 by miR-146a-5p increased susceptibility to myocardial ischaemic injury in aging mice.
    Cardiovasc Res. 2023;119:786-801.
    PubMed     Abstract available
    
    
    
33. PHANG RJ, Ritchie RH, Hausenloy DJ, Lees JG, et al
    Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy.
    Cardiovasc Res. 2023;119:668-690.
    PubMed     Abstract available
    
    
    March 2023
34. YANG X, Zhang M, Xie B, Peng Z, et al
    Myocardial brain-derived neurotrophic factor regulates cardiac bioenergetics through the transcription factor Yin Yang 1.
    Cardiovasc Res. 2023;119:571-586.
    PubMed     Abstract available
    
    
    
35. SAMUELSSON AM, Bartolomaeus TUP, Anandakumar H, Thowsen I, et al
    VEGF-B hypertrophy predisposes to transition from diastolic to systolic heart failure in hypertensive rats.
    Cardiovasc Res. 2023 Mar 23:cvad040. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. PARKSOOK WW, Williams GH
    Aldosterone and cardiovascular diseases.
    Cardiovasc Res. 2023;119:28-44.
    PubMed     Abstract available
    
    
    
37. FAYYAZ AU, Sabbah MS, Dasari S, Griffiths LG, et al
    Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension.
    Cardiovasc Res. 2023;119:268-282.
    PubMed     Abstract available
    
    
    
38. MARKOUSIS-MAVROGENIS G, Minich WB, Al-Mubarak AA, Anker SD, et al
    Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure.
    Cardiovasc Res. 2023 Mar 8:cvad042. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2023
39. 
    Corrigendum to: Global burden of heart failure: a comprehensive and updated review of epidemiology.
    Cardiovasc Res. 2023 Feb 9:cvad026. doi: 10.1093.
    PubMed    
    
    
    
40. CAPONE F, Sotomayor-Flores C, Bode D, Wang R, et al
    Cardiac metabolism in HFpEF: from fuel to signalling.
    Cardiovasc Res. 2023;118:3556-3575.
    PubMed     Abstract available
    
    
    
41. PORCARI A, Fontana M, Gillmore JD
    Transthyretin cardiac amyloidosis.
    Cardiovasc Res. 2023;118:3517-3535.
    PubMed     Abstract available
    
    
    
42. DULCE RA, Kanashiro-Takeuchi RM, Takeuchi LM, Salerno AG, et al
    Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction.
    Cardiovasc Res. 2023;118:3586-3601.
    PubMed     Abstract available
    
    
    January 2023
43. 
    Erratum to: Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions.
    Cardiovasc Res. 2023 Jan 21:cvad002. doi: 10.1093.
    PubMed    
    
    
    
44. RAGNI M, Greco CM, Felicetta A, Ren SV, et al
    Dietary essential amino acids for the treatment of heart failure with reduced ejection fraction.
    Cardiovasc Res. 2023 Jan 10:cvad005. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2022
45. THUM T, Lam CSP
    Accelerating developments in heart failure.
    Cardiovasc Res. 2022 Dec 30:cvac185. doi: 10.1093.
    PubMed    
    
    
    
46. VANHAVERBEKE M, Attard R, Bartekova M, Ben-Aicha S, et al
    Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: a position paper from the EU-CardioRNA COST action CA17129.
    Cardiovasc Res. 2022;118:3183-3197.
    PubMed     Abstract available
    
    
    
47. KHAN MS, Shahid I, Greene SJ, Mentz RJ, et al
    Mechanisms of current therapeutic strategies for heart failure: more questions than answers?
    Cardiovasc Res. 2022 Dec 20:cvac187. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. HUNKLER HJ, Gross S, Thum T, Bar C, et al
    Non-coding RNAs: key regulators of reprogramming, pluripotency, and cardiac cell specification with therapeutic perspective for heart regeneration.
    Cardiovasc Res. 2022;118:3071-3084.
    PubMed     Abstract available
    
    
    November 2022
49. PETERS AE, Tromp J, Shah SJ, Lam CSP, et al
    Phenomapping in heart failure with preserved ejection fraction - insights, limitations, and future directions.
    Cardiovasc Res. 2022 Nov 30:cvac179. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. LOESCHER CM, Hobbach AJ, Linke WA
    Titin (TTN): from molecule to modifications, mechanics, and medical significance.
    Cardiovasc Res. 2022;118:2903-2918.
    PubMed     Abstract available
    
    
    September 2022
51. VIDEIRA RF, Koop AMC, Ottaviani L, Poels EM, et al
    The adult heart requires baseline expression of the transcription factor Hand2 to withstand right ventricular pressure overload.
    Cardiovasc Res. 2022;118:2688-2702.
    PubMed     Abstract available
    
    
    
52. 
    Corrigendum to: Temporal relationship between systemic endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure.
    Cardiovasc Res. 2022 Sep 15. pii: 6698740. doi: 10.1093.
    PubMed    
    
    
    August 2022
53. MCKINSEY TA, Foo R, Anene-Nzelu CG, Travers JG, et al
    Emerging epigenetic therapies of cardiac fibrosis and remodeling in heart failure: from basic mechanisms to early clinical development.
    Cardiovasc Res. 2022 Aug 25. pii: 6675295. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. PUGLIESE NR, Pellicori P, Filidei F, De Biase N, et al
    Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions.
    Cardiovasc Res. 2022 Aug 25. pii: 6675297. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. JESON SANGARALINGHAM S, Kuhn M, Cannone V, Chen HH, et al
    Natriuretic peptide pathways in heart failure - further therapeutic possibilities.
    Cardiovasc Res. 2022 Aug 25. pii: 6675294. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. DE WIT S, Glen C, de Boer RA, Lang NN, et al
    Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies.
    Cardiovasc Res. 2022 Aug 25. pii: 6675097. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. THIELE A, Luettges K, Ritter D, Beyhoff N, et al
    Pharmacological inhibition of adipose tissue adipose triglyceride lipase by Atglistatin prevents catecholamine-induced myocardial damage.
    Cardiovasc Res. 2022;118:2488-2505.
    PubMed     Abstract available
    
    
    July 2022
58. SAVARESE G, Butler J, Lund LH, Bhatt DL, et al
    Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Cardiovasc Res. 2022;118:2231-2252.
    PubMed     Abstract available
    
    
    
59. BORLAUG BA, Jensen MD, Kitzman DW, Lam CSP, et al
    Obesity and heart failure with preserved ejection fraction: new insights and pathophysiologic targets.
    Cardiovasc Res. 2022 Jul 26. pii: 6649894. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. JANG AY, Scherer PE, Kim JY, Lim S, et al
    Adiponectin and cardiometabolic trait and mortality: where do we go?
    Cardiovasc Res. 2022;118:2074-2084.
    PubMed     Abstract available
    
    
    
61. SASSET L, Manzo OL, Zhang Y, Marino A, et al
    Nogo-A reduces ceramide de novo biosynthesis to protect from heart failure.
    Cardiovasc Res. 2022 Jul 11. pii: 6639610. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. KEEFE J, Wehrens XH, Dobrev D
    Common disease-promoting signaling pathways in heart failure and atrial fibrillation: putative underlying mechanisms and potential therapeutic consequences.
    Cardiovasc Res. 2022 Jul 5. pii: 6631397. doi: 10.1093.
    PubMed    
    
    
    June 2022
63. LUSCHER TF, Akhtar MM
    Looking deeper into takotsubo's heart.
    Cardiovasc Res. 2022;118:1851-1853.
    PubMed    
    
    
    
64. PORTERO V, Nicol T, Podliesna S, Marchal GA, et al
    Chronically elevated branched chain amino acid levels are pro-arrhythmic.
    Cardiovasc Res. 2022;118:1742-1757.
    PubMed     Abstract available
    
    
    
65. JACKSON MR, Cox KD, Baugh SDP, Wakeen L, et al
    Discovery of a first-in-class inhibitor of sulfide:quinone oxidoreductase that protects against adverse cardiac remodelling and heart failure.
    Cardiovasc Res. 2022;118:1771-1784.
    PubMed     Abstract available
    
    
    
66. KUMARI R, Ranjan P, Suleiman ZG, Goswami SK, et al
    mRNA modifications in cardiovascular biology and disease: with a focus on m6A modification.
    Cardiovasc Res. 2022;118:1680-1692.
    PubMed     Abstract available
    
    
    
67. DHINGRA R, Kirshenbaum LA
    ULK1 mediated mitophagy prevents pathological cardiac remodelling and heart failure.
    Cardiovasc Res. 2022 Jun 21. pii: 6612712. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. HERON C, Dumesnil A, Houssari M, Renet S, et al
    Regulation and impact of cardiac lymphangiogenesis in pressure-overload-induced heart failure.
    Cardiovasc Res. 2022 Jun 11. pii: 6605782. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2022
69. ROUHI L, Fan S, Cheedipudi SM, Braza-Boils A, et al
    The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure.
    Cardiovasc Res. 2022;118:1466-1478.
    PubMed     Abstract available
    
    
    April 2022
70. TUAL-CHALOT S, Stellos K
    Targeting the adipose tissue: heart crosstalk in pressure overload-induced heart failure.
    Cardiovasc Res. 2022 Apr 13. pii: 6568065. doi: 10.1093.
    PubMed    
    
    
    
71. 
    Corrigendum to: Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.
    Cardiovasc Res. 2022 Apr 9. pii: 6565889. doi: 10.1093.
    PubMed    
    
    
    March 2022
72. YU JK, Liang JA, Franceschi WH, Huang Q, et al
    Assessment of arrhythmia mechanism and burden of the infarcted ventricles following remuscularization with pluripotent stem cell-derived cardiomyocyte patches using patient-derived models.
    Cardiovasc Res. 2022;118:1247-1261.
    PubMed     Abstract available
    
    
    
73. GATICA D, Chiong M, Lavandero S, Klionsky DJ, et al
    The role of autophagy in cardiovascular pathology.
    Cardiovasc Res. 2022;118:934-950.
    PubMed     Abstract available
    
    
    
74. MURPHY KA, Harsch BA, Healy CL, Joshi SS, et al
    Free fatty acid receptor 4 responds to endogenous fatty acids to protect the heart from pressure overload.
    Cardiovasc Res. 2022;118:1061-1073.
    PubMed     Abstract available
    
    
    February 2022
75. PITOULIS FG, Nunez-Toldra R, Xiao K, Kit-Anan W, et al
    Remodelling of adult cardiac tissue subjected to physiological and pathological mechanical load in vitro.
    Cardiovasc Res. 2022;118:814-827.
    PubMed     Abstract available
    
    
    
76. SAVARESE G, Becher PM, Lund LH, Seferovic P, et al
    Global burden of heart failure: A comprehensive and updated review of epidemiology.
    Cardiovasc Res. 2022 Feb 12. pii: 6527627. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2022
77. BERTERO E, Dudek J, Cochain C, Delgobo M, et al
    Immuno-metabolic interfaces in cardiac disease and failure.
    Cardiovasc Res. 2022;118:37-52.
    PubMed     Abstract available
    
    
    December 2021
78. BENN M, Marott SCW, Tybjaerg-Hansen A, Nordestgaard BG, et al
    Obesity increases heart failure incidence and mortality: observational and Mendelian randomisation studies totalling over 1 million individuals.
    Cardiovasc Res. 2021 Dec 25. pii: 6483090. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. KARWI QG, Ho KL, Pherwani S, Ketema EB, et al
    Corrigendum to: Concurrent diabetes and heart failure: interplay and novel therapeutic approaches.
    Cardiovasc Res. 2021 Dec 13. pii: 6460360. doi: 10.1093.
    PubMed    
    
    
    October 2021
80. SANTEMA BT, Arita VA, Sama IE, Kloosterman M, et al
    Pathophysiological pathways in patients with heart failure and atrial fibrillation.
    Cardiovasc Res. 2021 Oct 23. pii: 6409189. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. MOHAISSEN T, Proniewski B, Targosz-Korecka M, Bar A, et al
    Temporal relationship between systemic endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure.
    Cardiovasc Res. 2021 Oct 7. pii: 6383136. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2021
82. DAVIDSON SM, Padro T, Bollini S, Vilahur G, et al
    Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart.
    Cardiovasc Res. 2021;117:2161-2174.
    PubMed     Abstract available
    
    
    
83. CAMPBELL H, Aguilar-Sanchez Y, Quick AP, Dobrev D, et al
    SPEG: a key regulator of cardiac calcium homeostasis.
    Cardiovasc Res. 2021;117:2175-2185.
    PubMed     Abstract available
    
    
    
84. FERREIRA JP, Ouwerkerk W, Santema BT, van Veldhuisen DJ, et al
    Differences in biomarkers and molecular pathways according to age for patients with HFrEF.
    Cardiovasc Res. 2021;117:2228-2236.
    PubMed     Abstract available
    
    
    
85. RICHARDS AM
    Proteomic probing for markers and mechanisms in Heart Failure.
    Cardiovasc Res. 2021 Aug 10. pii: 6347578. doi: 10.1093.
    PubMed    
    
    
    July 2021
86. ZHAO B, Bouchareb R, Lebeche D
    Resistin deletion protects against heart failure injury by targeting DNA damage response.
    Cardiovasc Res. 2021 Jul 29. pii: 6330773. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. ABDELLATIF M, Lam CSP
    Scientists on the Spot: A fraction of wisdom on heart failure.
    Cardiovasc Res. 2021;117:e114-e115.
    PubMed    
    
    
    
88. VOLPE M, Gallo G
    Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists.
    Cardiovasc Res. 2021;117:1992-1994.
    PubMed    
    
    
    
89. MARKOUSIS-MAVROGENIS G, Tromp J, Ouwerkerk W, Fereirra JP, et al
    Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.
    Cardiovasc Res. 2021 Jul 15. pii: 6321950. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. DIEZ J, de Boer RA
    Management of cardiac fibrosis is the largest unmet medical need in heart failure Cardiac fibrosis in heart failure.
    Cardiovasc Res. 2021 Jul 9. pii: 6318397. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. GRASSI G, Mancia G, Esler M
    CENTRAL AND PERIPHERAL SYMPATHETIC ACTIVATION IN HEART FAILURE.
    Cardiovasc Res. 2021 Jul 7. pii: 6317668. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2021
92. ONODI Z, Ruppert M, Kucsera D, Sayour AA, et al
    AIM2-driven inflammasome activation in heart failure.
    Cardiovasc Res. 2021 Jun 12. pii: 6297397. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. SANSONETTI M, De Windt LJ
    Non-coding RNAs in cardiac inflammation: key drivers in the pathophysiology of heart failure.
    Cardiovasc Res. 2021 Jun 7. pii: 6294284. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. NAUMENKO N, Mutikainen M, Holappa L, Ruas JL, et al
    PGC-1alpha deficiency reveals sex-specific links between cardiac energy metabolism and EC-coupling during development of heart failure in mice.
    Cardiovasc Res. 2021 Jun 4. pii: 6292089. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2021
95. TAO Z, Loo S, Su L, Tan S, et al
    Angiopoietin-1 enhanced myocyte mitosis, engraftment, and the reparability of hiPSC-CMs for treatment of myocardial infarction.
    Cardiovasc Res. 2021;117:1578-1591.
    PubMed     Abstract available
    
    
    
96. 
    Corrigendum to: Heart failure or heart success?
    Cardiovasc Res. 2021 May 18. pii: 6277376. doi: 10.1093.
    PubMed    
    
    
    April 2021
97. MONMA Y, Shindo T, Eguchi K, Kurosawa R, et al
    Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction.
    Cardiovasc Res. 2021;117:1325-1338.
    PubMed     Abstract available
    
    
    
98. 
    Retraction: Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure.
    Cardiovasc Res. 2021 Apr 22. pii: 6245632. doi: 10.1093.
    PubMed    
    
    
    
99. BOLLI R, Solankhi M, Tang XL, Kahlon A, et al
    Cell Therapy in Patients with Heart Failure: A Comprehensive Review and Emerging Concepts.
    Cardiovasc Res. 2021 Apr 19. pii: 6237881. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2021
100. KARWI QG, Ho KL, Pherwani S, Ketema EB, et al
     Concurrent diabetes and heart failure: interplay and novel therapeutic approaches.
     Cardiovasc Res. 2021 Mar 30. pii: 6203809. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. SELVARAJ S, Margulies KB
     Exogenous ketones in the healthy heart: the plot thickens.
     Cardiovasc Res. 2021;117:995-996.
     PubMed    
     
     
     
102. BAUERSACHS J
     SCORED and SOLOIST: the next scores for SGLT2 inhibitors.
     Cardiovasc Res. 2021;117:e49-e51.
     PubMed    
     
     
     
103. ABE I, Terabayashi T, Hanada K, Kondo H, et al
     Disruption of actin dynamics regulated by Rho effector mDia1 attenuates pressure overload-induced cardiac hypertrophic responses and exacerbates dysfunction.
     Cardiovasc Res. 2021;117:1103-1117.
     PubMed     Abstract available
     
     
     
104. TAKAHARA S, Soni S, Maayah ZH, Ferdaoussi M, et al
     Ketone Therapy for Heart Failure: Current Evidence for Clinical Use.
     Cardiovasc Res. 2021 Mar 10. pii: 6168424. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. CUOMO A, Pirozzi F, Tocchetti CG
     Low-intensity pulsed ultrasound (LIPUS) in heart failure with preserved ejection fraction (HFpEF): lupus in fabula?
     Cardiovasc Res. 2021 Mar 5. pii: 6159769. doi: 10.1093.
     PubMed    
     
     
     February 2021
106. LUXAN G, Dimmeler S
     The vasculature: a therapeutic target in heart failure?
     Cardiovasc Res. 2021 Feb 23. pii: 6146925. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. TERAMOTO K, Tromp J, Lam CSP
     Heart failure or heart success?
     Cardiovasc Res. 2021 Feb 13. pii: 6134544. doi: 10.1093.
     PubMed    
     
     
     
108. DE LUCIA C, Grisanti LA, Borghetti G, Piedepalumbo M, et al
     GRK5 contributes to impaired cardiac function and immune cell recruitment in post-ischemic heart failure.
     Cardiovasc Res. 2021 Feb 9. pii: 6131786. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2021
109. HEGYI B, Ko CY, Bossuyt J, Bers DM, et al
     Two-hit mechanism of cardiac arrhythmias in diabetic hyperglycemia: reduced repolarization reserve, neurohormonal stimulation and heart failure exacerbate susceptibility.
     Cardiovasc Res. 2021 Jan 23. pii: 6105172. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. CICCARELLI M, Dawson D, Falcao-Pires I, Giacca M, et al
     Reciprocal organ interactions during heart failure-a position paper from the ESC working group on myocardial function.
     Cardiovasc Res. 2021 Jan 22. pii: 6105178. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. TOENNIS T, Kirchhof P
     Connecting the dots? Rate control, heart failure, and atrial fibrillation.
     Cardiovasc Res. 2021;117:336-337.
     PubMed    
     
     
     
112. PANENI F, Sciarretta S, Costantino S
     Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?
     Cardiovasc Res. 2021;117:343-345.
     PubMed    
     
     
     
113. GUICHARD JB, Xiong F, Qi XY, L'Heureux N, et al
     Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodelling.
     Cardiovasc Res. 2021;117:462-471.
     PubMed     Abstract available
     
     
     
114. LIMA CORREA B, El Harane N, Gomez I, Rachid Hocine H, et al
     Extracellular vesicles from human cardiovascular progenitors trigger a reparative immune response in infarcted hearts.
     Cardiovasc Res. 2021;117:292-307.
     PubMed     Abstract available
     
     
     November 2020
115. MELI AC, Fischmeister R
     Scientists on the spot: Phosphodiesterases and heart failure.
     Cardiovasc Res. 2020 Nov 1. pii: 5952729. doi: 10.1093.
     PubMed    
     
     
     October 2020
116. NAKAMURA M, Odanovic N, Nakada Y, Dohi S, et al
     Dietary Carbohydrates Restriction Inhibits The Development Of Cardiac Hypertrophy And Heart Failure.
     Cardiovasc Res. 2020 Oct 18. pii: 5929700. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. PANICO C, Kallikourdis M, Condorelli G
     Defining circulating mononuclear cells in heart failure through single-cell RNA sequencing: new insights for an old disease.
     Cardiovasc Res. 2020 Oct 13. pii: 5922371. doi: 10.1093.
     PubMed    
     
     
     
118. LANG NN, Dobbin SJH, Petrie MC
     Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial.
     Cardiovasc Res. 2020;116:e152-e155.
     PubMed    
     
     
     July 2020
119. MELI AC, de Tombe P
     Scientists on the Spot: Myocardium and myofilaments.
     Cardiovasc Res. 2020;116:e96-e97.
     PubMed    
     
     
     March 2020
120. VAN BERLO JH, Garry DJ
     Hearts and Hands: the good, the bad, and the ugly.
     Cardiovasc Res. 2020;116:470-472.
     PubMed    
     
     
     
121. VOLLAND C, Schott P, Didie M, Manner J, et al
     Control of p21Cip by BRCA1-associated protein is critical for cardiomyocyte cell cycle progression and survival.
     Cardiovasc Res. 2020;116:592-604.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.